First-line Carboplatin and Paclitaxel in Combination With Pembrolizumab, Followed by Maintenance Pembrolizumab With or Without Nesuparib, in Patients With Newly Diagnosed Advanced or Recurrent MMR-proficient (pMMR) Endometrial Cancer

NCT06502743 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

92

Enrollment

OTHER

Sponsor class

Conditions

Endometrial Cancer
Recurrent Endometrial Carcinoma
Endometrial Carcinoma
Gynecologycal Cancer
Endometrial Neoplasms

Interventions

DRUG: Nesuparib
DRUG: Pembrolizumab

Sponsor

Yonsei University

Collaborators

[object Object]
[object Object]